Sanofi to Showcase Broad Dermatology and Immunology Data at EADV 2025

Sanofi to Showcase Broad Dermatology and Immunology Data at EADV 2025

By, Admin 4 September 2025

Sanofi will present 45 abstracts, including 4 oral presentations, at the European Academy of Dermatology and Venereology (EADV) Congress in Paris from September 17–20, 2025. The data spans both approved therapies and investigational medicines, with a focus on Dupixent and candidates from Sanofi’s immunology pipeline.

Spotlight on Dupixent (Developed with Regeneron)

Sanofi and Regeneron will present data highlighting Dupixent’s impact across multiple chronic inflammatory skin diseases:

  • Atopic Dermatitis (AD)
    - LIBERTY PEDS AD (NCT03345914): Effect of Dupixent on growth in children with AD.
    - DISCOVER (NCT05590585): Evaluation of skin structure in patients with skin of colour using 3D imaging.
    - Extension and real-world studies: Outcomes up to four years in children with skin of colour.
  • Prurigo Nodularis (PN)
    - PRIME & PRIME2 (NCT04183335, NCT04202679): Dupixent’s impact on lesions, itch, pain, stinging, and the emotional burden of PN.
  • Chronic Spontaneous Urticaria (CSU)
    - CUPID A & C (NCT04180488): Effects on itch and hives, including early and sustained responses.

Safety outcomes were generally consistent with the known Dupixent safety profile.

New Data from Sanofi’s Immunology Pipeline

  • Brivekimig (Dual TNF + OX40L Inhibitor, Nanobody)
    - HS-OBTAIN Phase 2a (NCT05849922): First 16-week results in moderate-to-severe hidradenitis suppurativa (HS).
  • Amlitelimab (Anti-OX40L mAb)
    - STREAM-AD Phase 2b (NCT05131477): 52-week data on maintenance of response in AD.
  • Rilzabrutinib (Oral BTK Inhibitor)
    - RILECSU Phase 2 (NCT05107115): 12-week results on angioedema in CSU patients.
  • SAR445399 (IL1R3 mAb)
    - Proof-of-mechanism study: Reduction of skin inflammation via IL1 and IL36 pathways.

Brivekimig, amlitelimab, and rilzabrutinib remain investigational; no conclusions on efficacy or safety should be drawn.

Executive Commentary

Alyssa Johnsen, MD, PhD, Global Head of Immunology & Oncology Development, Sanofi:

“Our broad EADV data set reflects our commitment to advancing therapies for chronic inflammatory skin diseases. Dupixent data further support its role in AD, PN, and CSU, while the first results for brivekimig in HS highlight the potential of dual TNF and OX40L inhibition.”

About Dupixent

  • Mechanism: Fully human mAb blocking IL-4 and IL-13 signaling, key drivers of type 2 inflammation.
  • Regulatory status: Approved in 60+ countries across multiple indications, including AD, PN, CSU, asthma, CRSwNP, eosinophilic esophagitis, COPD, and bullous pemphigoid.
  • Global use: >1 million patients treated.
  • Development: Jointly developed by Sanofi & Regeneron, studied in 60+ trials with >10,000 patients.
  • Ongoing research: Expanding into new indications such as chronic pruritus of unknown origin and lichen simplex chronicus.

About Sanofi’s Pipeline

  • Brivekimig: Dual TNF/OX40L nanobody, investigated across HS, AD, IBD, type 1 diabetes, and kidney disorders.
  • Amlitelimab: OX40L blocker aiming to restore immune balance with potential quarterly dosing.
  • Rilzabrutinib: Oral BTK inhibitor developed with Tailored Covalency tech to reduce off-target risks.
  • SAR445399: Novel IL1R3-targeting mAb for IL1/IL36-driven inflammation.

About Sanofi

Sanofi is an R&D-driven, AI-powered biopharma company, committed to delivering transformative therapies across immunology, oncology, rare diseases, and vaccines.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!